KI-Beratung Beta

Produktbild: Cuproptosis in Oncology
Vorbesteller Neu

Cuproptosis in Oncology Pathogenic Mechanisms and Emerging Therapeutic Opportunities

214,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Cuproptosis in Oncology: Pathogenic Mechanisms and Emerging Therapeutic Opportunities offers a comprehensive study of this novel form of regulated cell death driven by copper-induced mitochondrial stress, and its significance in cancer. The book begins with foundational chapters on the fundamentals...

Beschreibung

Cuproptosis in Oncology: Pathogenic Mechanisms and Emerging Therapeutic Opportunities offers a comprehensive study of this novel form of regulated cell death driven by copper-induced mitochondrial stress, and its significance in cancer. The book begins with foundational chapters on the fundamentals of cuproptosis, its molecular mechanisms, and significance of copper homeostasis in cellular physiology, setting the stage for advanced discussions on its role in oncogenesis. Subsequent sections investigate cuproptosis in cancer progression, including how dysregulated cuproptosis influences tumor initiation, proliferation, metastasis, and therapy resistance. This is followed by an evaluation of innovative therapeutic approaches, including copper chelators, nanomedicine, small-molecule modulators, and combination therapies, highlighting their potential to revolutionize cancer treatment. The final section considers translational and clinical perspectives, including cuproptosis biomarkers for diagnosis and prognosis in oncology, clinical trials targeting cuproptosis, and future perspectives regarding the integration of omics, systems biology and precision medicine for therapeutic innovation. This volume unearths the critical role of copper homeostasis in tumor development and progression, laying the foundation for future translational advances. It serves as an invaluable resource for biomedical researchers including cell biologists, pharmacologists and oncologists, seeking to understand and target copper-dependent cell death pathways.

Portrait

Dr. Gourav Singh is an Assistant Professor at Amity Institute of Pharmacy, India, and a researcher in medicinal chemistry with a keen focus on neurodegenerative diseases, especially Alzheimer's disease (AD). His research has centered on the rational design, synthesis, and biological evaluation of small molecules aimed at therapeutic intervention. Dr. Singh has co-authored research articles in a number of journals. With a strong interdisciplinary foundation spanning organic synthesis, computational drug design, and biological validation, Dr. Singh effectively bridges chemistry and neuropharmacology. His work significantly advances translational drug discovery efforts targeting neurodegenerative disorders.

Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer reviewed research and review articles in high impact journals, received multiple international awards, and serves on the editorial boards of several international journals.

Dr. Krishan Kumar is an Assistant Professor of Pharmaceutics at Amity Institute of Pharmacy, Amity University, Noida, India. His research expertise encompasses targeted and controlled drug delivery, nanomedicine, nano-therapeutics for cancer therapeutics. He has authored and co-authored research articles, review articles, book chapters, and patents in advanced drug delivery for cancer therapy. His research background closely aligns with Cuproptosis in Oncology: Pathogenic Mechanisms and Emerging Therapeutic Opportunities, particularly its focus on nanomedicine-based therapeutic strategies, targeted drug delivery, and translational approaches for exploiting emerging cancer cell-death mechanisms. His expertise in developing targeted nano-therapeutics provides a strong pharmaceutical and drug-delivery perspective to the book’s discussion of cuproptosis-based strategies and precision cancer therapeutics.

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at the University School of Pharmaceutical Sciences, Rayat Bahra University, Sahauran, India. His research interests include nano-formulation, cancer biology, and neuroscience, alongside digital and computational approaches such as machine learning, artificial intelligence, big data analytics, blockchain, and the Internet of Things. He has contributed academic books, book chapters, and review articles in pharmaceutical sciences and healthcare technology, with a focus on interdisciplinary approaches that integrate pharmaceutical research with emerging digital technologies.

Dr. Himanshu Rai is a Postdoctoral Fellow in the Department of Biochemistry at the Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada, supported by a CIHR Canada Impact+ Research Training Award (CIRTA). Working with Dr. Kun Ping Lu, he develops inhibitors and theranostic agents for neurodegenerative diseases and cancer models. His earlier research focused on near-infrared (NIR) fluorescent theranostic probes for detecting pathological biomarkers of Alzheimer’s disease. He previously worked in pharmaceutical R&D at Piramal Discovery Solutions and Mankind Research Centre on small-molecule discovery programmes, including JAK-1 inhibitors and GPR119 agonists. His work integrates synthetic medicinal chemistry, computational modelling, and in vitro and in vivo imaging. He has published as lead author in journals including Nature Communications and the Journal of Medicinal Chemistry, and is a named inventor on several patents.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.06.2027

Herausgeber Gourav Singh + weitere
Verlag Elsevier

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.06.2027

Herausgeber
Verlag Elsevier
Seitenzahl

550

Maße (L/B)

23,5/19,1 cm

Sprache

Englisch

ISBN

978-0-443-53992-3

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Cuproptosis in Oncology
  • Section I: Foundations of cuproptosis and cancer biology
    1. Introduction to cuproptosis: Discovery and conceptual framework
    2. Copper homeostasis in cellular physiology
    3. Mitochondrial metabolism and the TCA cycle in cuproptosis
    4. Molecular mechanisms of cuproptosis
    5. Hallmarks of cancer and copper dysregulation

    Section II: Cuproptosis in cancer progression
    6. Cuproptosis and tumor initiation
    7. Cuproptosis and cancer cell proliferation
    8. Angiogenesis, metastasis, and the role of cuproptosis
    9. Cuproptosis and tumor microenvironment (TME)
    10. Cuproptosis in therapy resistance

    Section III: Therapeutic opportunities and innovations
    11. Copper chelators and ionophores in cancer therapy
    12. Nanomedicine approaches to induce cuproptosis
    13. Small-molecule modulators of cuproptosis
    14. Combination therapies involving cuproptosis
    15. Natural products and cuproptosis induction

    Section IV: Translational and clinical perspectives
    16. Cuproptosis biomarkers in oncology
    17. Preclinical models and clinical trials targeting cuproptosis
    18. Future directions: Cuproptosis in precision oncology